Radionuclide Theranostics: the Potential in Neuroendocrine Tumours

Date: 11 November 2016, Friday
Time: 4.30pm - 6.00pm
Venue: Seminar Room L1-S3, Level 1, Academia, Singapore General Hospital Campus
             (20 College Road, Singapore 169856)

Speaker

Dr Philip E Harris PhD FRCP FRSB​

Philip E Harris trained in endocrinology at the University of Wales College of Medicine, St Bartholomew’s Hospital, London, the University of Newcastle-upon-Tyne and Massachusetts General Hospital, Boston. In 1994, he was appointed Senior Lecturer and Honorary Consultant Endocrinologist at King’s College Hospital, London.  Although his main role is now in the pharmaceutical industry, he remains clinically active. In 2001, he was appointed Director Adult Endocrinology at Pharmacia and subsequently Senior Director and Head of Endocrinology Clinical Development at Pfizer.  Dr Harris is currently Vice President Scientific Affairs at Ipsen Biopharma. His main focus is in the development of strategically aligned early opportunities in neuroendocrine disease, with academic and industrial collaborations and the identification of opportunities for in-licensing and acquisition. Dr Harris has a key role in the development of Ipsen’s strategy in radiotheranostics, with products currently in development for neuroendocrine tumours and pancreatic cancer. 

Click here to download flyer.

Limited seats available! To RSVP, email to [email protected].